While completely blocking astrocytic NF-κB signaling may not be a feasible therapeutic approach due to the diversity of associated processes, restoring downstream effects such as complement C3, AQP4, and mitochondrial function could significantly enhance the management of AD. Here, NFKB1 is linked to Alzheimer disease.